Osphos is an injectable bisphosphonate solution for control of clinical signs associated with navicular syndrome in horses four years of age and older. Osphos inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts. Osphos contains 60 mg/ml clodronate disodium in a ready-to-use injection. Osphos is administered IM at 1.8 mg/kg, up to a maximum dose of 900 mg (one 15 ml vial) per horse. Divide the total volume evenly into three separate injection sites. Discard unused vial contents. Osphos may be recommended at 3-6 month intervals, based on evaluation and recurrence of clinical signs. Clodronate disodium.
Shipping Restrictions: The following may not be shippable to the specified states: GU, VI
